Bristol-Myers Wins Investor Support For $74B Celgene Buy
Bristol-Myers Squibb shareholders on Friday voted in favor of the pharmaceutical company's planned $74 billion acquisition of Celgene, overcoming pushback on the deal from an activist hedge fund and an institutional...To view the full article, register now.
Already a subscriber? Click here to view full article